Safety and Effectiveness of Biktarvy ® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea

Infection and Chemotherapy 2026 Open access

Read full text
Authors: Shin‐Woo Kim, Jami Peters, Markus G. Lang, J. Lee, Jinhye Cha, Yeon-Sook Kim
DOI: 10.3947/ic.2025.0140
Cited by: 0
References: 7

Abstract

year surveillance period of a prospective, multicenter, observational, post-marketing surveillance study that evaluates the safety and effectiveness of Biktarvy in routine clinical practice in Korea. A total of 1,157 patients were included in the safety analysis set. Most patients were male (93.3%) and ART experienced (treatment-experienced [89.3%]). Adverse events occurred in 425 patients (36.7%) and of those 63 patients reported adverse drug reactions (ADRs [5.5%]). No serious ADRs were reported. The virological success rate (HIV-1 RNA

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV-related health complications and treatments

Publication details

Journal / source
Infection and Chemotherapy
Volume
58
Issue
1
Pages
122–122
Publication date
1 January 2026
Language
EN